6-gingerol inhibits rosiglitazone-induced adipogenesis in 3T3-L1 adipocytes

Phytother Res. 2014 Feb;28(2):187-92. doi: 10.1002/ptr.4976. Epub 2013 Mar 21.

Abstract

We investigated the effects of 6-gingerol ((S)-5-hydroxy-1-(4-hydroxy-3-methoxyphenyl)-3-decanone) on the inhibition of rosiglitazone (RGZ)-induced adipogenesis in 3T3-L1 cells. The morphological changes were photographed based on staining lipid accumulation by Oil-Red O in RGZ (1 µmol/l)-treated 3T3-L1 cells without or with various concentrations of 6-gingerol on differentiation day 8. Quantitation of triglycerides content was performed in cells on day 8 after differentiation induction. Differentiated cells were lysed to detect mRNA and protein levels of adipocyte-specific transcription factors by real-time reverse transcription-polymerase chain reaction and Western blot analysis, respectively. 6-gingerol (50 µmol/l) effectively suppressed oil droplet accumulation and reduced the sizes of the droplets in RGZ-induced adipocyte differentiation in 3T3-L1 cells. The triglyceride accumulation induced by RGZ in differentiated 3T3-L1 cells was also reduced by 6-gingerol (50 µmol/l). Treatment of differentiated 3T3-L1 cells with 6-gingerol (50 µmol/l) antagonized RGZ-induced gene expression of peroxisome proliferator-activated receptor (PPAR)γ and CCAAT/enhancer-binding protein α. Additionally, the increased levels of mRNA and protein in adipocyte-specific fatty acid binding protein 4 and fatty acid synthase induced by RGZ in 3T3-L1 cells were decreased upon treatment with 6-gingerol. Our data suggests that 6-gingerol may be beneficial in obesity, by reducing adipogenesis partly through the down-regulating PPARγ activity.

Keywords: 3T3-L1 cells; 6-gingerol; adipogenesis; peroxisome proliferator-activated receptor γ; rosiglitazone.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 3T3-L1 Cells
  • Adipocytes / cytology
  • Adipocytes / drug effects*
  • Adipocytes / metabolism
  • Adipogenesis / drug effects*
  • Animals
  • CCAAT-Enhancer-Binding Protein-alpha / antagonists & inhibitors
  • CCAAT-Enhancer-Binding Protein-alpha / genetics
  • CCAAT-Enhancer-Binding Protein-alpha / metabolism
  • Catechols / pharmacology*
  • Cell Differentiation / drug effects
  • Down-Regulation / drug effects
  • Fatty Acid Synthases / genetics
  • Fatty Acid Synthases / metabolism
  • Fatty Acid-Binding Proteins / genetics
  • Fatty Acid-Binding Proteins / metabolism
  • Fatty Alcohols / pharmacology*
  • Mice
  • Obesity
  • PPAR gamma / antagonists & inhibitors
  • PPAR gamma / genetics
  • PPAR gamma / metabolism
  • RNA, Messenger / genetics
  • RNA, Messenger / metabolism
  • Rosiglitazone
  • Thiazolidinediones / adverse effects*
  • Triglycerides / metabolism

Substances

  • CCAAT-Enhancer-Binding Protein-alpha
  • Catechols
  • Fabp4 protein, mouse
  • Fatty Acid-Binding Proteins
  • Fatty Alcohols
  • PPAR gamma
  • RNA, Messenger
  • Thiazolidinediones
  • Triglycerides
  • Rosiglitazone
  • gingerol
  • Fatty Acid Synthases